Significant Shareholder Joseph S. Freedman Increases Stake by $2.33M
EPRX has more than doubled off its 52-week low of $2.68 on elevated volume (2.7× avg).
Summary
Significant shareholder Joseph S. Freedman increased his stake in Eupraxia Pharmaceuticals by $2.33 million through recent purchases and warrant exercises, demonstrating strong insider confidence.
Key Events · Ownership and Investor Activity · EPRX
-
Insider Purchases in Public Offering
On February 20, 2026, Joseph S. Freedman and his spouse purchased a combined 280,000 common shares at $7.00 per share in an underwritten public offering, for an aggregate of $1,960,000.
-
Warrant Exercises by Affiliated Entities
On February 27, 2026, a trust for which Mr. Freedman serves as trustee, and his minor children, exercised warrants to acquire 170,000 common shares at an exercise price of $2.20 per share, totaling $374,000.
-
Increased Beneficial Ownership
Following these transactions, Joseph S. Freedman's beneficial ownership increased to 5,843,215 shares, representing 9.0% of the company's common shares.
Analysis · EPRX · Life Sciences
Joseph S. Freedman, a significant individual shareholder, has substantially increased his beneficial ownership in Eupraxia Pharmaceuticals through a series of purchases and warrant exercises totaling $2.33 million. This includes participation in a public offering and the exercise of warrants by his trust and children. This significant insider buying, occurring shortly before the company's 40-F filing on March 13, 2026, which reported an extended cash runway, signals strong confidence in the company's future prospects and financial stability.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EPRX was trading at $7.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.3M. The 52-week trading range was $2.68 to $9.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.